Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction

Drug Metabolism and Disposition

Volumn 36, Issue 11, 2008, Pages 2355-2370

  Shou, Magang ^a   Hayashi, Mike ^a   Pan, Yvonne ^a   Xu, Yang ^a   Morrissey, Kari ^a   Xu, Lilly ^a   Skiles, Gary L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMPRENAVIR; ATORVASTATIN; BOSENTAN; BUDESONIDE; BUSPIRONE; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DEXAMETHASONE; EFAVIRENZ; ETHINYLESTRADIOL; GLIBENCLAMIDE; INDINAVIR; LOSARTAN; METHADONE; NIFEDIPINE; PHENAZONE; PHENOBARBITAL; PRAVASTATIN; QUINIDINE; RIFAMPICIN; RITONAVIR; SILDENAFIL; SIMVASTATIN; TIRILAZAD; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; COMPUTER MODEL; COMPUTER PREDICTION; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; ENZYME INDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER METABOLISM; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; BENZOXAZINES; CARBAMAZEPINE; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FEMALE; HEPATOCYTES; HUMANS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PREDICTIVE VALUE OF TESTS; SUBSTRATE SPECIFICITY; SULFONAMIDES;

EID: 54349113314     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020602     Document Type: Article

References (189)

1. Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, and Burger DM (2002) The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 71:57-67.
2. Achira M, Suzuki H, Ito K, and Sugiyama Y (1999) Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS Pharmsci 1:E18.
3. Adams M, Pieniaszek HJ Jr, Gammaitoni AR, and Ahdieh H (2005) Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 45:337-345.
4. Ahonen J, Olkkola KT, and Neuvonen PJ (1996) The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 10:314-318.
5. Araki K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Inoue Y, Tateishi T, and Otani K (2004) Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 60:427-430.
6. Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503.
7. Back DJ, Bates M, Bowden A, Breckenridge AM, Hall MJ, Jones H, MacIver M, Orme M, Perucca E, Richens A, et al. (1980) The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 22:495-503.
8. Back DJ, Breckenridge AM, Crawford F, MacIver M, Orme ML, Park BK, Rowe PH, and Smith E (1979) The effect of rifampicin on norethisterone pharmacokinetics. Eur J Clin Pharmacol 15:193-197.
9. Backman JT, Kivistö KT, Olkkola KT, and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58.
10. Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, and Neuvonen PJ (2006) Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 62:345-357.
11. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
12. Backman JT, Luurila H, Neuvonen M, and Neuvonen PJ (2005) Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78:154-167.
13. Backman JT, Olkkola KT, and Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13.
14. Barbarash RA, Bauman JL, Fischer JH, Kondos GT, and Batenhorst RL (1988) Near-total reduction in verapamil bioavailability by rifampin: electrocardiographic correlates. Chest 94:954-959.
15. Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, Hendrix CW, and Flexner C (1999) The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 65:428-438.
16. Bennett PN, John VA, and Whitmarsh VB (1982) Effect of rifampicin on metoprolol and antipyrine kinetics. Br J Clin Pharmacol 13:387-391.
17. Bergrem H and Refvem OK (1983) Altered prednisolone pharmacokinetics in patients treated with rifampicin. Acta Med Scand 213:339-343.
18. Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, and Brøsen K (2004) Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 60:109-114.
19. Binet I, Wallnöfer A, Weber C, Jones R, and Thiel G (2000) Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int 57:224-231.
20. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, and Seiberling M (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102-106.
21. Boyd MA, Aarnoutse RE, Ruxrungtham K, Stek M Jr, van Heeswijk RP, Lange JM, Cooper DA, Phanuphak P, and Burger DM (2003a) Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. J Acquir Immune Defic Syndr 34:134-139.
22. Boyd MA, Zhang X, Dorr A, Ruxrungtham K, Kolis S, Nieforth K, Kinchelow T, Buss N, and Patel IH (2003b) Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 43:1382-1391.
23. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
24. Chandler MH, Toler SM, Rapp RP, Muder RR, and Korvick JA (1990) Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. Antimicrob Agents Chemother 34:442-447.
25. Chen M, Nafziger AN, and Bertino JS Jr (2006) Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab Dispos 34:2079-2082.
26. Chung E, Nafziger AN, Kazierad DJ, and Bertino JS Jr (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79:350-361.
27. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, and Back DJ (2001) The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 51:213-217.
28. Cobb MN, Desai J, Brown LS Jr, Zannikos PN, and Rainey PM (1998) The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 63:655-662.
29. Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19:317-366.
30. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, and Orme M (1990) The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 30:892-896.
31. Damkier P, Hansen LL, and Brosen K (1999) Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 48:829-838.
32. Daniels NJ, Dover JS, and Schachter RK (1984) Interaction between cyclosporin and rifampicin. Lancet 2:639.
33. Data JL, Wilkinson GR, and Nies AS (1976) Interaction of quinidine with anticonvulsant drugs. N Engl J Med 294:699-702.
34. de Leon J and Bork J (1997) Risperidone and cytochrome P450 3A (see comment). J Clin Psychiatry 58:450.
35. Dickinson BD, Altman RD, Nielsen NH, Sterling ML, and Council on Scientific Affairs AMA (2001) Drug interactions between oral contraceptives and antibiotics (see comment). Obstet Gynecol 98:853-860.
36. Dilger K, Denk A, Heeg MH, and Beuers U (2005) No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 41:595-602.
37. Dingemanse J, Schaarschmidt D, and van Giersbergen PL (2003) Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet 42:293-301.
38. D'Mello AP, D'Souza MJ, and Bates TR (1985) Pharmacokinetics of ketoconazole-antipyrine interaction. Lancet 2:209-210.
39. Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, and Bialer M (2003) Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44:540-549.
40. Droste JA, Verweij-van Wissen CP, Kearney BP, Buffels R, Vanhorssen PJ, Hekster YA, and Burger DM (2005) Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 49:680-684.
41. Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, and Standiford HC (1986) Steadystate serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother 30:42-45.
42. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, and Seiberling M (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54:290-294.
43. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, et al. (2004) Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60:237-246.
44. Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, et al. (2000) Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 30:313-318.
45. Ferron GM, Patat A, Parks V, Rolan P, and Troy SM (2003) Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 56:39-45.
46. Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, and Peters GR (1996) Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther 277:991-998.
47. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
48. Fromm MF, Busse D, Kroemer HK, and Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801.
49. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, and Klotz U (1998) Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol 45:247-255.
50. Fuhr U, Müller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S, and Staib AH (2002) Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol 58:45-53.
51. Furukori H, Kondo T, Yasui N, Otani K, Tokinaga N, Nagashima U, Kaneko S, and Inoue Y (1999) Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Psychopharmacology 145:189-192.
52. Furukori H, Otani K, Yasui N, Kondo T, Kaneko S, Shimoyama R, Ohkubo T, Nagasaki T, and Sugawara K (1998) Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 18:364-369.
53. Galetin A, Burt H, Gibbons L, and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175.
54. Galetin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190.
55. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA, and AIDS Clinical Trials Group (2005) Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 39:307-312.
56. Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, McWilliams EJ, and McCrea JB (1996) Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 59:268-274.
57. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
58. Goodwin B, Hodgson E, and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329-1339.
59. Gorski JC, Jones DR, Wrighton SA, and Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes: contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182.
60. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, and Hall SD (2003) The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. [Erratum appears in Clin Pharmacol Ther (2004) 75:249]. Clin Pharmacol Ther 74:275-287.
61. Goujard C, Vincent I, Meynard JL, Choudet N, Bollens D, Rousseau C, Demarles D, Gillotin C, Bidault R, and Taburet AM (2003) Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 47:118-123.
62. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, and Shader RI (1999) Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 19:293-296.
63. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, and Shader RI (2000) Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24:129-136.
64. Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, and Shader RI (1998) Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 64:237-247.
65. Grimm SW, Richtand NM, Winter HR, Stams KR, and Reele SB (2006) Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 61:58-69.
66. Grub S, Bryson H, Goggin T, Lüdin E, and Jorga K (2001) The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 57:115-121.
67. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
68. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, and Cheboyina S (2006) Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 46:201-213.
69. He N, Huang SL, Zhu RH, Tan ZR, Liu J, Zhu B, and Zhou HH (2003) Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent. Xenobiotica 33:211-221.
70. Hebert MF, Fisher RM, Marsh CL, Dressler D, and Bekersky I (1999) Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39:91-96.
71. Hebert MF, Roberts JP, Prueksaritanont T, and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
72. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, and Goulart DA (1987) The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 42:388-394.
73. Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
74. Hilbert J, Messig M, Kuye O, and Friedman H (2001) Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. Obstet Gynecol 98:218-223.
75. Hillebrand G, Castro LA, van Scheidt W, Beukelmann D, Land W, and Schmidt D (1987) Valproate for epilepsy in renal transplant recipients receiving cyclosporine (see comment). Transplantation 43:915-916.
76. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, and Heidemann H (1996) The nifedipinerifampin interaction: evidence for induction of gut wall metabolism (see comment). Drug Metab Dispos 24:1121-1123.
77. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, and Cantilena LR (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences (see comment). [Erratum appears in JAMA (1993) 269:2088]. JAMA 269:1513-1518.
78. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM, et al. (1998) Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 42:2784-2791.
79. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, et al. (2003) Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 47:350-359.
80. Humbert G, Brumpt I, Montay G, Le Liboux A, Frydman A, Borsa-Lebas F, and Moore N (1991) Influence of rifampin on the pharmacokinetics of pefloxacin. Clin Pharmacol Ther 50:682-687.
81. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
82. Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94:1140-1146.
83. Jokinen MJ, Ahonen J, Neuvonen PJ, and Olkkola KT (2001a) Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. Pharmacol Toxicol 88:187-191.
84. Jokinen MJ, Olkkola KT, Ahonen J, and Neuvonen PJ (2001b) Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol Ther 70:344-350.
85. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, et al. (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27-39.
86. Kapil RP, Axelson JE, Mansfield IL, Edwards DJ, McErlane B, Mason MA, Lalka D, and Kerr CR (1987) Disopyramide pharmacokinetics and metabolism: effect of inducers. Br J Clin Pharmacol 24:781-791.
87. Kato M, Chiba K, Horikawa M, and Sugiyama Y (2005) The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 20:236-243.
88. Kaukonen KM, Olkkola KT, and Neuvonen PJ (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 53:445-449.
89. Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, Callahan AM, Hinton ML, Chao J, and Post RM (1995) Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 15:327-333.
90. Khaliq Y, Gallicano K, Venance S, Kravcik S, and Cameron DW (2000) Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 68:637-646.
91. Kharasch ED, Hoffer C, Whittington D, and Sheffels P (2004a) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269.
92. Kharasch ED, Walker A, Hoffer C, and Sheffels P (2004b) Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 76:452-466.
93. Kharasch ED, Walker A, Hoffer C, and Sheffels P (2005) Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. J Clin Pharmacol 45:1187-1197.
94. Kim KA, Oh SO, Park PW, and Park JY (2005) Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol 61:275-280.
95. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
96. Kivistö KT, Lamberg TS, Kantola T, and Neuvonen PJ (1997) Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole (see comment). Clin Pharmacol Ther 62:348-354.
97. Kivistö KT, Lamberg TS, and Neuvonen PJ (1999) Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Pharmacol Toxicol 84:94-97.
98. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82.
99. Kondo S, Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Inoue Y, Tateishi T, and Otani K (2005) Induction of the metabolism of etizolam by carbamazepine in humans. Eur J Clin Pharmacol 61:185-188.
100. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, and Schmouder RL (2005) Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur J Clin Pharmacol 61:35-38.
101. Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, and Rordorf C (2002) Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 36:981-985.
102. Kremens B, Brendel E, Bald M, Czyborra P, and Michel MC (1999) Loss of blood pressure control on withdrawal of fluconazole during nifedipine therapy. Br J Clin Pharmacol 47:707-708.
103. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
104. Kuypers DR, Verleden G, Naesens M, and Vanrenterghem Y (2005) Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphateglucuronosyltransferase. Clin Pharmacol Ther 78:81-88.
105. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, and Neuvonen PJ (2000) Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68:592-597.
106. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
107. Lamberg TS, Kivistö KT, and Neuvonen PJ (1998) Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol 45:381-385.
108. la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, Koopmans PP, Hekster YA, and Burger DM (2004a) Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 48:1553-1560.
109. la Porte CJ, de Graaff-Teulen MJ, Colbers EP, Voncken DS, Ibanez SM, Koopmans PP, Hekster YA, and Burger DM (2004b) Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. Br J Clin Pharmacol 58:632-640.
110. Laroudie C, Salazar DE, Cosson JP, Cheuvart B, Istin B, Girault J, Ingrand I, and Decourt JP (2000) Carbamazepine-nefazodone interaction in healthy subjects. J Clin Psychopharmacol 20:46-53.
111. LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallée F, and Narang PK (1998) Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol 38:1042-1050.
112. Leclercq V, Desager JP, Horsmans Y, Van Nieuwenhuyze Y, and Harvengt C (1989) Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. Int J Clin Pharmacol Ther Toxicol 27:593-598.
113. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, and Parkinson A (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-188.
114. Licht RW, Olesen OV, Friis P, and Laustsen T (2000) Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine. J Clin Psychopharmacol 20:110-112.
115. Lilja JJ, Niemi M, Fredrikson H, and Neuvonen PJ (2007) Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 63:732-740.
116. Lobell M and Sivarajah V (2003) In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol Divers 7:69-87.
117. Lopez-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón- González A, Gómez-Mateos J, León-Jimenez E, Sarasanacenta M, López-Pua Y, and Pachón J (2002) Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 41:681-690.
118. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, et al. (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804.
119. Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, LeCluyse E, Solon E, Brennan JM, et al. (2003) Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos 31:1170-1175.
120. Masimirembwa CM, Thompson R, and Andersson TB (2001) In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screen 4:245-263.
121. Masui T, Kusumi I, Takahashi Y, and Koyama T (2006) Effect of carbamazepine on the single oral dose pharmacokinetics of perospirone and its active metabolite. Prog Neuropsychopharmacol Biol Psychiatry 30:1330-1333.
122. May TW, Rambeck B, and Jürgens U (1996) Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 18:523-531.
123. May TW, Rambeck B, and Jürgens U (2003) Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 25:690-699.
124. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, and Sundaresen P (2000) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 68:391-400.
125. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, and Lindley C (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68:356-366.
126. Mills JB, Rose KA, Sadagopan N, Sahi J, and de Morais SM (2004) Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 309:303-309.
127. Moore JT and Kliewer SA (2000) Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153:1-10.
128. Moore MJ, Hardy RW, Thiessen JJ, Soldin SJ, and Erlichman C (1988) Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 44:622-628.
129. Morse GD, Rosenkranz S, Para MF, Segal Y, Difrancesco R, Adams E, Brizz B, Yarasheski KE, and Reichman RC (2005) Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob Agents Chemother 49:3373-3381.
130. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, and Watkins PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72:1-9.
131. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, and Buss N (2000) Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir (see comment). Br J Clin Pharmacol 50:99-107.
132. Neuvonen PJ, Kantola T, and Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341.
133. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, and Kivistö KT (2000) Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 68:495-500.
134. Niemi M, Neuvonen PJ, and Kivistö KT (2001) The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 70:58-65.
135. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
136. Ohnhaus EE, Brockmeyer N, Dylewicz P, and Habicht H (1987) The effect of antipyrine and rifampin on the metabolism of diazepam. Clin Pharmacol Ther 42:148-156.
137. Olivesi A (1986) Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother 40:301-308.
138. Otani K, Ishida M, Kaneko S, Mihara K, Ohkubo T, Osanai T, and Sugawara K (1996a) Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Ther Drug Monit 18:164-167.
139. Otani K, Yasui N, Kaneko S, Ohkubo T, Osanai T, and Sugawara K (1996b) Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int Clin Psychopharmacol 11:55-57.
140. Paul GA, Gibbs JS, Boobis AR, Abbas A, and Wilkins MR (2005) Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 60:107-112.
141. Phimmasone S and Kharasch ED (2001) A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther 70:505-517.
142. Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Lou Y, Kristoff D, and Stein DS (2001) Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 45:502-508.
143. Polk RE, Crouch MA, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WT, Gouldin W, and Lou Y (1999) Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 19:1378-1384.
144. Powell-Jackson PR, Gray BJ, Heaton RW, Costello JF, Williams R, and English J (1983) Adverse effect of rifampicin administration on steroid-dependent asthma. Am Rev Respir Dis 128:307-310.
145. Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH, and Baillie TA (1999) Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations (see comment). Br J Clin Pharmacol 47:291-298.
146. Prueksaritanont T, Vega JM, Zhao J, Gagliano K, Kuznetsova O, Musser B, Amin RD, Liu L, Roadcap BA, Dilzer S, et al. (2001) Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 41:573-581.
147. Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, and Kivistö KT (2002) Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther 72:362-369.
148. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, and de Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742-1748.
149. Rutledge DR, Pieper JA, and Mirvis DM (1988) Effects of chronic phenobarbital on verapamil disposition in humans. J Pharmacol Exp Ther 246:7-13.
150. Saccar CL, Danish M, Ragni MC, Rocci ML Jr, Greene J, Yaffe SJ and Mansmann HC Jr (1985) The effect of phenobarbital on theophylline disposition in children with asthma. J Allergy Clin Immunol 75:716-719.
151. Schellens JH, van der Wart JH, Brugman M, and Breimer DD (1989) Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 249:638-645.
152. Schlienger R, Kurmann M, Drewe J, Müller-Spahn F, and Seifritz E (2000) Inhibition of phenprocoumon anticoagulation by carbamazepine. Eur Neuropsychopharmacol 10:219-221.
153. Schmider J, Brockmöller J, Arold G, Bauer S, and Roots I (1999) Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics 9:725-734.
154. Schuetz EG, Beck WT, and Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
155. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, and Rodrigues AD (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375-388.
156. Sitsen J, Maris F, and Timmer C (2001) Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur J Drug Metab Pharmacokinet 26:109-121.
157. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, et al. (2004) Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 48:4306-4314.
158. Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, and Wild MJ (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44:1067-1081.
159. Tada Y, Tsuda Y, Otsuka T, Nagasawa K, Kimura H, Kusaba T, and Sakata T (1992) Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension. Am J Med Sci 303:25-27.
160. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
161. Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
162. Tran-Johnson T, Herrera JM, Sramek JJ, Costa JF, Heh C, and Pi E (1987) Time-dependent autoinduction of carbamazepine in schizophrenia. Drug Intell Clin Pharm 21:835.
163. Treiber A, Schneiter R, Häusler S, and Stieger B (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400-1407.
164. Tsuchihashi K, Fukami K, Kishimoto H, Sumiyoshi T, Haze K, Saito M, and Hiramori K (1987) A case of variant angina exacerbated by administration of rifampicin. Heart Vessels 3:214-217.
165. Tuteja S, Alloway RR, Johnson JA, and Gaber AO (2001) The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71:1303-1307.
166. Twum-Barima Y and Carruthers SG (1981) Quinidine-rifampin interaction. N Engl J Med 304:1466-1469.
167. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, and Mjörndal T (2004) Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 59:879-882.
168. van Giersbergen PL, Halabi A, and Dingemanse J (2002) Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 53:589-595.
169. van Giersbergen PL, Halabi A, and Dingemanse J (2006) Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 44:113-118.
170. Varhe A, Olkkola KT, and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607.
171. Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, Johnson M, Kwakkelstein MO, Carlier H, van Leeuwen R, et al. (2001) The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons (see comment). J Infect Dis 184:37-42.
172. Venkatakrishnan K and Obach RS (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 33:845-852.
173. Vignati LA, Bogni A, Grossi P, and Monshouwer M (2004) A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. Toxicology 199:23-33.
174. Villikka K, Kivistö KT, Backman JT, Olkkola KT, and Neuvonen PJ (1997a) Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 61:8-14.
175. Villikka K, Kivistö KT, Luurila H, and Neuvonen PJ (1997b) Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 62:629-634.
176. Villikka K, Kivisto KT, and Neuvonen PJ (1998) The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 83:135-138.
177. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
178. Wang RW, Newton DJ, Scheri TD, and Lu AY (1997) Human cytochrome P450 3A4-catalyzed testosterone 6β-hydroxylation and erythromycin N-demethylation: competition during catalysis. Drug Metab Dispos 25:502-507.
179. Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, and Thitiarchakul S (1995) Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Br J Clin Pharmacol 40:87-91.
180. Wanwimolruk S, Paine MF, Pusek SN, and Watkins PB (2002) Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4? Br J Clin Pharmacol 54:643-651.
181. Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, Khan A, Zhao Z, and Tuberculosis Trials Consortium (2005) Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 41:1343-1349.
182. Williamson KM, Patterson JH, McQueen RH, Adams KF Jr, and Pieper JA (1998) Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 63:316-323.
183. Wire MB, Ballow C, Preston SL, Hendrix CW, Piliero PJ, Lou Y, and Stein DS (2004) Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 18:897-907.
184. Williams K, Begg E, Wade D, and O'Shea K (1983) Effects of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination. Clin Pharmacol Ther 33:314-321.
185. Yasui-Furukori N, Kondo T, Mihara K, Suzuki A, Inoue Y, and Kaneko S (2003) Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. J Clin Psychopharmacol 23:435-440.
186. Yonemori K, Takeda Y, Toyota E, Kobayashi N, and Kudo K (2004) Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer. Int J Clin Oncol 9:206-209.
187. Yule SM, Walker D, Cole M, McSorley L, Cholerton S, Daly AK, Pearson AD, and Boddy AV (1999) The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos 27:417-421.
188. Zhang Y, Hsieh Y, Izumi T, Lin ET, and Benet LZ (1998) Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 287:246-252.
189. Zürcher RM, Frey BM, and Frey FJ (1989) Impact of ketoconazole on the metabolism of prednisolone (see comment). Clin Pharmacol Ther 45:366-372.